ArticleCancer cell2026
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.
Abstract read
In one paragraph
Article in Cancer cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Cancer Neuroscience: From Local Neuro-Immune Microenvironments to Systemic Brain-Body Circuitry.MedComm · 2026Review
- Plasticity of Non-Apoptotic Residual Tumor Cells After Neoadjuvant Immunochemotherapy: Epigenetic and Microenvironmental Determinants.Biomolecules · 2026Review
- Unveiling the sensing potential of innate lymphoid cells.Communications biology · 2026Review
- Deconstructing cancer in 3D: models, mechanisms, and personalized solutions.Molecular cancer · 2026Review
- cGAS-STING pathway regulated by spatiotemporal heterogeneity of tumor microenvironment and precision therapy strategies in lung cancer.Journal of experimental & clinical cancer research : CR · 2026Review
- A new era of natural killer cell immunotherapy in tumor treatment: latest advances and cutting-edge perspectives from basic research to clinical practice.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
63 authors.
Marco CampisiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Tatsuya OsakiPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Ian DrygCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Carla StornanteDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Mechanical and Aerospace Engineering, Politecnico di Torino, 10129 Turin, Italy.
Jacqueline WolffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jason WeiratherCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Nicholas WeaverCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Mubin TarannumDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ian GillandersDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Alan BersDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Eden BobilevDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Maia S LineberryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Pieter ScholDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Minyue ChenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Keiichi OtaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Sung R ParkDepartment of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Caroline G FaheyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard University, Cambridge, MA 02138, USA.
Tran C ThaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Yixiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Zhaorong LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ze-Hua LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Sarah SheltonDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Satomi HiroseDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Clare PadrickDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Elena IvanovaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Minh HaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Shaobo YangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Harrison OlszewskiCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Sophie KivlehanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Patrick LizotteDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Kelsey HagenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Iliana GjeciDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
William HallerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lauren M ZasadilDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Talal El ZarifDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jacob E BerchuckDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30307, USA.
Erik H KnelsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Elliott J BreaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Igor OdintsovDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Tianju LiuDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Valeria ChionoDepartment of Mechanical and Aerospace Engineering, Politecnico di Torino, 10129 Turin, Italy.
Bishma TuladharDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Kenneth NgoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Emily RosentraterTakeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA.
Jeffrey RaizerTakeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA.
Neil LineberryTakeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA.
Mriganka SurPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Kathleen PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Matthew FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
F Stephen HodiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Michael Y TolstorukovDepartment of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Matthew G OserDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Michal ShefferDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Constantine S MitsiadesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Ludwig Center at Harvard, Boston, MA 02215, USA.
Michael J BarnesCancer Immunology and Cell Therapy Research, Bristol Myers Squibb, Seattle, WA 98109, USA.
Vicky A ApplemanTakeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA.
Prafulla C GokhaleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Roger D KammDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Cloud P PaweletzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Rizwan RomeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Scott RodigCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: david_barbie@dfci.harvard.edu.
Navin R MahadevanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: navinmah@med.umich.edu.
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6MProject 3P50CA265826 · NCI · DANA-FARBER CANCER INST · PI Daniel Botelho Costa · 2022 to 2026
$13.7MStudying E-cadherin dynamics during extravasation and metastatic colonizationU54CA261694 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ROGER D KAMM · 2021 to 2026
$9.1MMicroRNA mechanisms of Rett SyndromeR01MH085802 · NIMH · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SUR, MRIGANKA · 2010 to 2025
$6.2MTargeting the cytokine circuitry of KRAS-driven lung cancerR01CA190394 · NCI · DANA-FARBER CANCER INST · PI David A Barbie · 2015 to 2026
$4.5MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MTransforming Genomics with 5 PB Big Omics Data Engine Cray CS300-AC SupercomputerS10OD018522 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2014 to 2014
$1.9MTargeting the immunologic vulnerabilities of small cell lung carcinomaK08CA270077 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Navin Mahadevan · 2022 to 2026
$1.0MNCI NIH HHS K08 CA270077NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA265826NCI NIH HHS R01 CA190394NCI NIH HHS U54 CA261694NIH HHS S10 OD018522NIH HHS S10 OD026880NIMH NIH HHS R01 MH085802
Abstract
Small cell lung cancer (SCLC) typically displays a "cold" tumor microenvironment with a paucity of immune infiltrate. Neuroendocrine SCLC cells also profoundly repress MHC-I expression, rendering them vulnerable to NK cell-mediated cytotoxicity. Here, we confirm that neuroendocrine SCLC cells are sensitive to NK cell-mediated attack, yet the quantitative spatial profiling of the SCLC immune microenvironment in patient samples reveals that effector immune cells, including NK cells, are excluded from MHC-I
Indexed as
Killer Cells, NaturalLung NeoplasmsMembrane ProteinsSmall Cell Lung CarcinomaAnimalsCell Line, TumorCytotoxicity, ImmunologicHumansMiceSignal TransductionSTING ProteinTumor MicroenvironmentMembrane ProteinsSTING1 protein, humanSTING Protein3D microphysiological systemsnatural killer cellssmall cell lung cancerspatial transcriptomics and proteomicsSTING agonismtumor-immune microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.